Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Clinical characteristics and progress of Kawasaki disease patients who had early treatment with intravenous immune globulin

가와사끼병에서 면역글로불린 조기 투여군의 임상적 특성 및 치료 경과

  • Park, So-Yoon (Department of Pediatrics, College of Medicine, Yeungnam University) ;
  • Lee, Young Hwan (Department of Pediatrics, College of Medicine, Yeungnam University)
  • 박소윤 (영남대학교 의과대학 소아과학교실) ;
  • 이영환 (영남대학교 의과대학 소아과학교실)
  • Received : 2007.07.21
  • Accepted : 2007.08.16
  • Published : 2007.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : To determine the optimal time of high dose intravenous immune globulin (IVIG) treatment, we analysed the clinical characteristics and progress of a group of Kawasaki disease patients who had early treatment with IVIG. Method : A retrospective study was conducted of 188 patients with Kawasaki disease who were admitted to Yeungnam University Medical Center from January 2000 to December 2005. All patients were treated with a high dose IVIG and high dose aspirin for the initial acute phase treatment. The early treatment group consisted of 94 patients who received treatment before 5 days of fever, and the conventional group consisted of 94 patients who were treated on or after day 5. The patients' sex, age, laboratory findings, total duration of fever, duration of fever after initial IVIG, need for additional IVIG and coronary artery status were noted. Result : There were no significant differences between the two groups in sex ratio and age. No significant differences were noted in the level of WBC count, ESR, CRP, serum albumin, LDH, total duration of fever and coronary abnormality. But the value of ALT($151.8{\pm}17.3$ vs. $81.9{\pm}13.4$, P=0.002), duration of fever after initial IVIG ($3.8{\pm}0.5days$ vs. $2.1{\pm}0.2days$, P=0.003), and rate of additional IVIG (15.9% vs. 6.3%, P=0.037) were significantly higher in the early treatment group. There was no significant difference in initial dose of IVIG, but dosage of aspirin was lower in early treatment group (P=0.037). Conclusion : There is no evidence that early treatment of IVIG has greater efficacy in preventing cardiac sequelae than conventional treatment. In addition, early treatment is likely to result in a greater requirement for additional IVIG treatment.

목 적 : 가와사끼병 환아를 대상으로 급성기 치료제인 고용량 IVIG 투여시기에 따른 환아들의 검사 소견, 임상 양상 및 예후를 분석하여 적절한 초회 IVIG 투여시기를 결정하는데 도움을 주고자 본 연구를 시행하였다. 방 법 : 영남대학교병원 소아과에서 최근 6년간 가와사끼병으로 입원하여 급성기 치료로 고용량 IVIG와 아스피린을 투여 받은 환아 188명(남 115명, 여 73명)을 대상으로 발열 5일 이내에 IVIG를 투여한 조기 투여군(94명)과 발열 5일 이후에 투여한 대조군(94명)으로 분류하여, 두 군 간의 성별, 연령, 급성기 혈액검사 소견, 총 발열 기간, 추가 발열 기간, IVIG 재치료율 및 관상동맥 합병증의 발생 빈도를 비교 분석하였다. 결 과 : 두 군 모두에서 남아가 더 많았으나, 두 군 간의 성별 및 평균 연령에서의 통계학적으로 유의한 차이는 없었다. 급성기 혈액 검사소견에서 WBC, ESR, CRP, LDH, 그리고 혈중 알부민 치는 두 군 간에 차이가 없었다. 하지만 ALT가 조기 투여군에서 의미 있게 높게 나타났으며, IVIG와 병용한 아스피린의 용량은 조기 투여군에서 낮게 나타났다. 치료 경과에서 총 발열 기간이나 관상동맥의 이상 유무에는 차이가 없었으며, IVIG 치료 후 추가 발열기간과 IVIG 재치료율 및 IVIG 총 투여량은 조기 투여군에서 의미있게 높았다. 결 론 : 소아의 가와사끼병에서 발열 5일 이내 고용량 IVIG 조기 투여 시 총 발열 기간이나 관상동맥 합병증의 감소 등의 효과는 나타나지 않았으며, 오히려 조기 투여군에서 IVIG 치료 후 추가 발열 기간 증가로 인해 IVIG 총 투여량 및 IVIG 재치료율이 높은 것으로 나타났다.

Keywords

References

  1. Freeman AF, Shulman ST. Kawasaki disease: summary of the American Heart Association guidelines. Am Fam Physician. 2006;74:1141-8
  2. Newburger JW, Takahashi M, Bums JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315: 341-7 https://doi.org/10.1056/NEJM198608073150601
  3. Yanagawa H, Nakimura Y, Yashiro M. The results of 16th nationwide survey of Kawasaki disease in Japan. J Pediatr Practice 2002;65:332-42
  4. Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, et al. Early intravenous gamma-globulin treatment for Kawasaki disease the nationwide surveys in Japan. J Pediatr 2004;144:496-9 https://doi.org/10.1016/j.jpeds.2003.12.033
  5. Research Committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health and Welfare;1984
  6. Sundel RP, Burns JC, Baker AS, Newburger JW, Gamma globulin retreatment in Kawasaki disease. J Pediatr 1993;123: 657-9 https://doi.org/10.1016/S0022-3476(05)80972-2
  7. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn J Allergy 1967;16:178-222
  8. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80 https://doi.org/10.1161/01.CIR.87.5.1776
  9. Ayusawa M, Sonobe T, Demara S: Revision of diagnostic guidelines for Kawasaki diseaserthe 5th revised edition). Pediatr Int 2005:47:232-4 https://doi.org/10.1111/j.1442-200x.2005.02033.x
  10. Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002;140:450-5 https://doi.org/10.1067/mpd.2002.122469
  11. SugaharaY, Ishii M, Muta H, Furui J, Himeno W, Akagi T. The effectiveness and safety of early intravenous immune globulin treatment for Kawasaki disease. 7th International Kawasaki Disease Symposium; December 4-7,2001 Hakone, Japan; Japan Kawasaki Disease Research Center, 2001
  12. Yanagawa H, Nakamura Y, Sakata K, Yashiro M. Use of intravenousgarnrna-globulin for Kawasaki disease: effects on cardiac sequelae. Pediatr Cardiol 1997;18:19-23 https://doi.org/10.1007/s002469900102
  13. Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr 2004;16:508-14 https://doi.org/10.1097/01.mop.0000137796.23813.64
  14. Onouchi Z, Kawasaki T. Overview of pharmacological treatment of Kawasaki disease. Drugs 1990;58:813-22 https://doi.org/10.2165/00003495-199958050-00004
  15. Nakamura Y, Yashiro M, Uehara R, Watanabe M, Tajimi M, Oki I, et, al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004:46:33-8 https://doi.org/10.1111/j.1442-200X.2004.01840.x
  16. Nomura Y, Masuda K, Yoshinaga M, Sameshima K, Miyaga K. Patients diagnosed with Kawasaki disease before the fifth day of illness have a higher risk of coronary artery aneurysm. Pediatr Int 2002:44:353-7 https://doi.org/10.1046/j.1442-200X.2002.01580.x
  17. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991;33:805-10 https://doi.org/10.1111/j.1442-200X.1991.tb02612.x
  18. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatrnent in Kawasaki disease. Pediatr Infect Dis J 1998;17:1144-8 https://doi.org/10.1097/00006454-199812000-00009
  19. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronaryartery lesions after intravenous gammaglobulin treatment in Kawasaki disease. J Pediatr 2000;137: 177-80 https://doi.org/10.1067/mpd.2000.107890
  20. Shim SY, Heo MY, Kim HS, Sonh SJ. High-dose intravenous immune globulin retreatment in Kawasaki disease. J Korean Pediatr Soc 2002:45:1273-7
  21. Kim EJ, Hong ME, Lee CW, Oh YG, Kim JD, Yoon HS. The clinical and laboratory features of Kawasaki disease with nonresponsibility to the acute antiinflammatory treatment. J Korean Pediatr Soc 2003:46:500-4
  22. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gamma globulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78 https://doi.org/10.1542/peds.105.6.e78
  23. Han RK, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 2000;154:694-9 https://doi.org/10.1001/archpedi.154.7.694